Literature DB >> 36097124

Simvastatin-loaded nano-niosomes efficiently downregulates the MAPK-NF-κB pathway during the acute phase of myocardial ischemia-reperfusion injury.

Maryam Naseroleslami1, Masoomeh Sharifi2,3, Neda Mousavi Niri4, Nahid Aboutaleb5,6.   

Abstract

BACKGROUND: Simvastatin can potentially mitigate acute inflammatory phase of myocardial ischemia-reperfusion injury. However, these effects negatively influenced by its poor bioavailability, low water solubility and high metabolism. Here, we investigated the effects of SIM-loaded nano-niosomes on a rat model of MI/R injury to find a drug delivery method to tackle the barriers.
METHODS: Nano-niosomes' characteristics were identified using dynamic light scattering and transmission electron microscopy. Fifty male Wistar rats were divided into five groups: Sham; MI/R; MI/R + nano-niosome; MI/R + SIM; MI/R + SIM-loaded nano-niosomes. Left anterior descending artery was ligated for 45 min, and 3 mg/kg SIM, nano-niosomes, or SIM-loaded nano-niosomes was intramyocardially injected ten min before the onset of reperfusion. ELISA assay was used to assess cardiac injury markers (cTnI, CK-MB) and inflammatory cytokines (TNF-α, IL-6, TGF-β, MPC-1). Expression level of MAPK-NF-κB and histopathological changes were evaluated by western blot and hematoxylin & eosin staining, respectively.
RESULTS: the size of nano-niosome was 137 nm, reached to 163 nm when simvastatin was loaded. To achieve optimized niosomes span 80, a drug/cholesterol ratio of 0.4 and seven min of sonication time was applied. Optimized entrapment efficiency of SIM-loaded nano-niosomes was 98.21%. Inflammatory cytokines and the expression level of MAPK and NF-κB were reduced in rats receiving SIM-loaded nano-niosomes compared to MI/R + SIM and MI/R + SIM-loaded nano-niosomes.
CONCLUSION: Our results showed that SIM-loaded nano-niosomes could act more efficiently than SIM in alleviating the acute inflammatory response of reperfusion injury via downregulating the activation of MAPK-NF-κB.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Drug delivery system; MAPK-NF-κB pathway; Myocardial ischemia/reperfusion injury; Nano-niosomes; Simvastatin

Year:  2022        PMID: 36097124     DOI: 10.1007/s11033-022-07891-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  33 in total

1.  FoxO1 and Wnt/β-catenin signaling pathway: Molecular targets of human amniotic mesenchymal stem cells-derived conditioned medium (hAMSC-CM) in protection against cerebral ischemia/reperfusion injury.

Authors:  Donya Nazarinia; Masoomeh Sharifi; Mojtaba Dolatshahi; Solmaz Nasseri Maleki; Arian Madani Neishaboori; Nahid Aboutaleb
Journal:  J Chem Neuroanat       Date:  2021-01-06       Impact factor: 3.052

2.  Urotensin-#receptor antagonist SB-706375 protected isolated rat heart from ischaemia-reperfusion injury by attenuating myocardial necrosis via RhoA/ROCK/RIP3 signalling pathway.

Authors:  Jing-Si Duan; Shuo Chen; Xiao-Qing Sun; Juan Du; Zhi-Wu Chen
Journal:  Inflammopharmacology       Date:  2019-06-05       Impact factor: 4.473

3.  Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019.

Authors:  Saeid Safiri; Nahid Karamzad; Kuljit Singh; Kristin Carson-Chahhoud; Cobi Adams; Seyed Aria Nejadghaderi; Amir Almasi-Hashiani; Mark J M Sullman; Mohammad Ali Mansournia; Nicola Luigi Bragazzi; Jay S Kaufman; Gary S Collins; Ali-Asghar Kolahi
Journal:  Eur J Prev Cardiol       Date:  2022-03-11       Impact factor: 7.804

Review 4.  Myocardial ischemia/reperfusion injury: Mechanisms of injury and implications for management (Review).

Authors:  Jianfeng He; Danyong Liu; Lixia Zhao; Dongcheng Zhou; Jianhui Rong; Liangqing Zhang; Zhengyuan Xia
Journal:  Exp Ther Med       Date:  2022-05-06       Impact factor: 2.751

Review 5.  Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

6.  Cardioprotection of vitexin on myocardial ischemia/reperfusion injury in rat via regulating inflammatory cytokines and MAPK pathway.

Authors:  Liu-Yi Dong; Sheng Li; Yi-Lan Zhen; Ya-Nan Wang; Xu Shao; Zhi-Gang Luo
Journal:  Am J Chin Med       Date:  2013       Impact factor: 4.667

Review 7.  Inhibition of Myocardial Cell Apoptosis Is Important Mechanism for Ginsenoside in the Limitation of Myocardial Ischemia/Reperfusion Injury.

Authors:  Zhihan Chen; Jingping Wu; Sijing Li; Caijiao Liu; Yulan Ren
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

Review 8.  Molecular-Signaling Pathways of Ginsenosides Rb in Myocardial Ischemia-Reperfusion Injury: A Mini Review.

Authors:  Fitri Fareez Ramli; Adli Ali; Nurul 'Izzah Ibrahim
Journal:  Int J Med Sci       Date:  2022-01-01       Impact factor: 3.738

9.  Ginsenoside Rb3 protects cardiomyocytes against ischemia-reperfusion injury via the inhibition of JNK-mediated NF-κB pathway: a mouse cardiomyocyte model.

Authors:  Lijia Ma; Huimin Liu; Zulong Xie; Shuang Yang; Wei Xu; Jingbo Hou; Bo Yu
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.